Intraperitoneal chemotherapy: a reemerging approach in the treatment of ovarian cancer.
Infusion of chemotherapy drugs through an intraperitoneal access device into the peritoneal cavity has reemerged as an approach that provides improved outcomes for patients with ovarian and other primary peritoneal cancers. This method allows for high concentrations of chemotherapy drugs to contact the tumor, surrounding tissues, and adjacent organs directly. The semipermeable membrane of the peritoneal cavity acts as a barrier and limits the passage of drugs in and out of the systemic circulation, thereby decreasing toxicity. This article discusses the physiology of peritoneal drug absorption, indications for use, the adverse effect profile and complications, and the administration technique.
Drake
Barbie
B
Oncology Services, Poudre Valley Hospital, Fort Collins, CO 80524, USA.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D057189:Checklist; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000451:nursing
D000970:Antineoplastic Agents